BRPI0409962A - co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente - Google Patents

co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente

Info

Publication number
BRPI0409962A
BRPI0409962A BRPI0409962-1A BRPI0409962A BRPI0409962A BR PI0409962 A BRPI0409962 A BR PI0409962A BR PI0409962 A BRPI0409962 A BR PI0409962A BR PI0409962 A BRPI0409962 A BR PI0409962A
Authority
BR
Brazil
Prior art keywords
excipient
active substance
formulation
pharmaceutical
particulate
Prior art date
Application number
BRPI0409962-1A
Other languages
English (en)
Inventor
Stephen Ernest Walker
Caroline Sophie German
Linda Sharon Daintree
Original Assignee
Nektar Therapeutics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0310636A external-priority patent/GB0310636D0/en
Application filed by Nektar Therapeutics Uk Ltd filed Critical Nektar Therapeutics Uk Ltd
Publication of BRPI0409962A publication Critical patent/BRPI0409962A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"CO-FORMULAçãO PARTICULADA DE UMA SUBSTáNCIA ATIVA E UM EXCIPIENTE, COMPOSIçãO FARMACêUTICA OU NUTRICêUTRICA, PRODUTO FARMACêUTICO OU NUTRICêUTICO, MéTODO PARA PREPARAR UMA CO-FORMULAçãO PARTICULADA DE UMA SUBSTáNCIA ATIVA E UM EXCIPIENTE, E, USO DE UMA SUBSTáNCIA ATIVA E UM EXCIPIENTE". Uma co-formulação particulada, cada partícula compreendendo um núcleo de uma substância ativa envolvido por um revestimento do excipiente, as partículas tendo um diâmetro de partícula médio em volume de (10) <109>m ou menos, a qual em administração oral libera a substância ativa a uma taxa tal que o tempo (T~ max~) levado para alcançar a concentração ativa máxima da substância ativa na corrente sanguinea do paciente é uma hora ou menos. A co-formulação pode ser produzida usando um processo de formação de partícula de SFC Nektar<32>.
BRPI0409962-1A 2003-05-08 2004-05-05 co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente BRPI0409962A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310636A GB0310636D0 (en) 2003-05-08 2003-05-08 Particulate materials
GB0329964A GB0329964D0 (en) 2003-05-08 2003-12-24 Particulate materials
PCT/GB2004/001935 WO2004098561A2 (en) 2003-05-08 2004-05-05 Particulate materials

Publications (1)

Publication Number Publication Date
BRPI0409962A true BRPI0409962A (pt) 2006-04-25

Family

ID=32510407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409962-1A BRPI0409962A (pt) 2003-05-08 2004-05-05 co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente

Country Status (10)

Country Link
US (1) US7354601B2 (pt)
EP (1) EP1624862B1 (pt)
JP (1) JP2006525303A (pt)
KR (1) KR20060015587A (pt)
AU (1) AU2004237131B2 (pt)
BR (1) BRPI0409962A (pt)
CA (1) CA2524773C (pt)
GB (1) GB2401547B (pt)
MX (1) MXPA05011343A (pt)
WO (1) WO2004098561A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974595B1 (en) 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
US7687542B2 (en) 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US20040251192A1 (en) * 2003-05-02 2004-12-16 Karl Fritze Crossflow filtration system with quick dry change elements
JP2006525303A (ja) 2003-05-08 2006-11-09 ネクター セラピューティクス ユーケー リミティド 微粒子物質
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
JP2007176869A (ja) * 2005-12-28 2007-07-12 Univ Meijo 難溶性薬物含有微細粒子
US7700125B2 (en) 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
US7939561B2 (en) 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
ES2390183T3 (es) 2006-10-11 2012-11-07 Crititech, Inc. Método de precipitación de partículas pequeñas de medicamento en recipiente de uso
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
EA201391742A1 (ru) * 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
JP2021028305A (ja) * 2019-08-09 2021-02-25 株式会社リコー 粒子、医薬組成物、及び粒子の製造方法
CN115321908B (zh) * 2022-08-10 2023-05-16 河南金诺混凝土有限公司 基于高品质机制砂的高性能混凝土及其制备方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418247B (sv) 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4582731A (en) 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
US4514574A (en) 1984-01-09 1985-04-30 The Dow Chemical Company Process for separating isomeric mixtures
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4737384A (en) 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
US5219575A (en) 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
ES2043640T3 (es) 1987-12-21 1994-01-01 Union Carbide Corp Fluidos supercriticos como diluyentes en la aplicacion por rociada liquida de revestimientos.
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
JPH01176437A (ja) 1987-12-29 1989-07-12 Ono Pharmaceut Co Ltd 有機物質の微粒化方法
US5066522A (en) 1988-07-14 1991-11-19 Union Carbide Chemicals And Plastics Technology Corporation Supercritical fluids as diluents in liquid spray applications of adhesives
DE68907062T2 (de) 1988-10-05 1993-10-07 Upjohn Co Feinverteiltes feste kristalline pulver durch niederschlag in einem anti-lösungsmittel.
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5232707A (en) 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5106659A (en) 1989-10-04 1992-04-21 Nordson Corporation Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas
US4970093A (en) 1990-04-12 1990-11-13 University Of Colorado Foundation Chemical deposition methods using supercritical fluid solutions
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US5037912A (en) 1990-07-26 1991-08-06 The Goodyear Tire & Rubber Company Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
DE4118230A1 (de) 1990-12-20 1992-06-25 Bayer Ag Verfahren zur isolierung von polymeren aus ihren loesungsmitteln mit kohlendioxid-haltigen fluessigkeiten
DE4041563A1 (de) 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
DE4117751A1 (de) 1991-05-30 1992-12-03 Bayer Ag Verfahren zur isolierung von polycarbonaten
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5196575A (en) 1992-02-19 1993-03-23 Hoechst Celanese Corp. Supercritical separation of isomers of functional organic compounds at moderate conditions
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
CA2145626A1 (en) 1992-11-02 1994-05-11 Frederick S. Mandel Method of preparing coating materials
EP0612697B1 (de) 1993-02-24 1998-01-21 Sulzer Chemtech AG Reinigung von salzbeladenem Abwasser durch Nassoxidation bei superkritischen Bedingungen
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
NZ276277A (en) 1993-11-08 1998-04-27 Gillette Co Antiperspirant compound, in aerogel form, being an aluminium salt, a zirconium salt or an aluminium-zirconium salt
IT1265473B1 (it) 1993-12-30 1996-11-22 Otefal Srl Procedimento per la produzione di polveri a granulometria controllata e prodotto in polvere cosi' ottenuto
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
SI9400079B (sl) 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5560543A (en) 1994-09-19 1996-10-01 Board Of Regents, The University Of Texas System Heat-resistant broad-bandwidth liquid droplet generators
MX9504934A (es) 1994-12-12 1997-01-31 Morton Int Inc Revestimientos en polvo de pelicula delgada lisa.
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
ES2306452T3 (es) 1995-10-17 2008-11-01 Jagotec Ag Aporte de farmacos insolubles.
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
EP0885038B1 (en) 1996-03-01 2011-06-15 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
FR2753639B1 (fr) 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
AU753476B2 (en) 1998-11-25 2002-10-17 Cima Labs, Inc. Taste masking rapid release coating system
SE9901667D0 (sv) 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
EP1478349A1 (en) 2002-02-21 2004-11-24 Amarin Development AB A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
AU2003209673B2 (en) 2002-03-08 2007-10-18 M/S. Ind-Swift Limited Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
JP2006525303A (ja) 2003-05-08 2006-11-09 ネクター セラピューティクス ユーケー リミティド 微粒子物質

Also Published As

Publication number Publication date
EP1624862A2 (en) 2006-02-15
KR20060015587A (ko) 2006-02-17
MXPA05011343A (es) 2005-12-12
US20050170000A1 (en) 2005-08-04
WO2004098561A3 (en) 2005-09-01
GB2401547B (en) 2005-07-20
GB2401547A (en) 2004-11-17
CA2524773C (en) 2014-04-08
AU2004237131B2 (en) 2009-09-10
AU2004237131A1 (en) 2004-11-18
WO2004098561A2 (en) 2004-11-18
CA2524773A1 (en) 2004-11-18
EP1624862B1 (en) 2014-12-31
GB0409973D0 (en) 2004-06-09
US7354601B2 (en) 2008-04-08
JP2006525303A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
Venook et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
MXPA05011343A (es) Materiales particulados.
BG105033A (bg) Фармацевтични състави за аерозоли с две, или повече активни вещества
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
DE69425932D1 (de) Schnellauflösliche pharmazeutische Dosierungsformen und Verfahren zu ihrer Herstellung
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
FI20002215A0 (fi) Yhdistelmäpartikkelit
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
FI971880A0 (fi) Helposti sulavan kantajan sisältävä farmaseuttinen koostumus ja menetelmä sen valmistamiseksi
HUP0401224A2 (hu) Eljárás gyógyászati készítmények előállítására lágyzselatin-összetételekkel való felhasználás céljára
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
JP6042696B2 (ja) 防已含有組成物
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
DE69918961D1 (de) Verbesserte inhalationspräparate
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
EA200500387A1 (ru) Композиции для ингаляции с высоким содержанием лекарственных веществ
JP6196847B2 (ja) 防已含有組成物
FI3930691T3 (fi) Asetominofeenia ja ibuprofeenia sisältävä lääkekoostumus
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]